JPRN-UMIN000005847招募中未知
Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectiveness - Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectiveness
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients unsuitable for Sorafenib Allergic reaction to Sorafenib, Pregnant women, Poor renal function(required hemodialysis), Past history of thromboembolism or ischemic heart disease Poor control of hypertension 2.Severe vascular invasion(Vp3,4)
研究者
相似试验
招募中
不适用
Different therapies other than Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectivenessHepatocellular carcinomaJPRN-UMIN000005848Kyoto university hospital50
招募中
2 期
To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000007488ippon medical school100
已完成
2 期
Investigating the role of targeted therapy Sorafenib - the Fms-like tyrosine kinase 3 (FLT3) inhibitor, in combination with intensive chemotherapy, for previously untreated adult patients with Acute Myeloid Leukaemia (AML) with FLT3 mutations. A Phase II randomised placebo-controlled multi-centre studyPreviously untreated adult acute myeloid leukaemia (AML) with FLT3-ITD mutation.Cancer - Leukaemia - Acute leukaemiaACTRN12611001112954eukaemia Foundation of Australia98
尚未招募
不适用
Efficacy and Safety of Sorafenib in Previously treated Advanced Hepatocellular Carcinoma: SOPT studyNeoplasmsKCT0006739ational Cancer Center50
进行中（未招募）
不适用
Sorafenib in the first line treatment of advanced hepatocellular carcinoma with ChildPugh liver function class B. Multicentre phase 3 randomized trial - BOOSTadvanced hepatocellular carcinoma with ChildPugh liver function class BMedDRA version: 9.1Level: LLTClassification code 10024720EUCTR2009-013870-42-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE